BACKGROUND: Recent evidence suggests that women who receive treatment for breast cancer may experience multiple symptoms that decrease their functional status and quality of life. Few studies evaluated the occurrence, severity, and distress of multiple symptoms in women at the initiation of radiation therapy (RT) for breast cancer. OBJECTIVE: This study evaluated for differences in symptoms occurrence, severity, and distress between women with breast cancer who did and did not receive chemotherapy (CTX) prior to RT. METHODS: Prior to the initiation of RT, patients completed the Memorial Symptom Assessment Scale (MSAS) that evaluated multiple dimensions of 32 symptoms. Differences in occurrence, severity, and distress scores between the 2 CTX groups were evaluated using χ and Mann-Whitney U tests. RESULTS: The 5 symptoms with the highest occurrence rates were lack of energy, worrying, difficulty sleeping, feeling drowsy, sweats, and pain. Women who received CTX prior to RT experienced twice as many symptoms as women who did not receive CTX. Except from difficulty sleeping, the 5 most prevalent symptoms were not the most severe or distressing. A poorer functional status, a higher comorbidity score, and previous CTX were all predictors of a higher number of symptoms. CONCLUSIONS: Women with breast cancer experience large numbers of symptoms at the initiation of RT. Previous CTX doubles the number of symptoms that women report. IMPLICATIONS FOR PRACTICE: Findings suggest that clinicians need to use a multidimensional symptom assessment tool in women with breast cancer at the initiation of RT.
BACKGROUND: Recent evidence suggests that women who receive treatment for breast cancer may experience multiple symptoms that decrease their functional status and quality of life. Few studies evaluated the occurrence, severity, and distress of multiple symptoms in women at the initiation of radiation therapy (RT) for breast cancer. OBJECTIVE: This study evaluated for differences in symptoms occurrence, severity, and distress between women with breast cancer who did and did not receive chemotherapy (CTX) prior to RT. METHODS: Prior to the initiation of RT, patients completed the Memorial Symptom Assessment Scale (MSAS) that evaluated multiple dimensions of 32 symptoms. Differences in occurrence, severity, and distress scores between the 2 CTX groups were evaluated using χ and Mann-Whitney U tests. RESULTS: The 5 symptoms with the highest occurrence rates were lack of energy, worrying, difficulty sleeping, feeling drowsy, sweats, and pain. Women who received CTX prior to RT experienced twice as many symptoms as women who did not receive CTX. Except from difficulty sleeping, the 5 most prevalent symptoms were not the most severe or distressing. A poorer functional status, a higher comorbidity score, and previous CTX were all predictors of a higher number of symptoms. CONCLUSIONS:Women with breast cancer experience large numbers of symptoms at the initiation of RT. Previous CTX doubles the number of symptoms that women report. IMPLICATIONS FOR PRACTICE: Findings suggest that clinicians need to use a multidimensional symptom assessment tool in women with breast cancer at the initiation of RT.
Authors: Christine Miaskowski; Andrea Barsevick; Ann Berger; Rocco Casagrande; Patricia A Grady; Paul Jacobsen; Jean Kutner; Donald Patrick; Lani Zimmerman; Canhua Xiao; Martha Matocha; Sue Marden Journal: J Natl Cancer Inst Date: 2017-01-24 Impact factor: 13.506
Authors: Fay Wright; Gail D'Eramo Melkus; Marilyn Hammer; Brian L Schmidt; M Tish Knobf; Steven M Paul; Frances Cartwright; Judy Mastick; Bruce A Cooper; Lee-May Chen; Michelle Melisko; Jon D Levine; Kord Kober; Bradley E Aouizerat; Christine Miaskowski Journal: J Pain Symptom Manage Date: 2015-03-28 Impact factor: 3.612
Authors: Nikolaos Papachristou; Payam Barnaghi; Bruce Cooper; Kord M Kober; Roma Maguire; Steven M Paul; Marilyn Hammer; Fay Wright; Jo Armes; Eileen P Furlong; Lisa McCann; Yvette P Conley; Elisabeth Patiraki; Stylianos Katsaragakis; Jon D Levine; Christine Miaskowski Journal: Sci Rep Date: 2019-02-19 Impact factor: 4.379
Authors: Kord M Kober; Laura Dunn; Judy Mastick; Bruce Cooper; Dale Langford; Michelle Melisko; Alan Venook; Lee-May Chen; Fay Wright; Marilyn Hammer; Brian L Schmidt; Jon Levine; Christine Miaskowski; Bradley E Aouizerat Journal: Biol Res Nurs Date: 2016-03-08 Impact factor: 2.522
Authors: Lindsey E Bischel; Christine Ritchie; Kord M Kober; Steven M Paul; Bruce A Cooper; Lee-May Chen; Jon D Levine; Marilyn Hammer; Fay Wright; Christine Miaskowski Journal: Eur J Oncol Nurs Date: 2016-07-15 Impact factor: 2.398
Authors: Kord M Kober; Bruce A Cooper; Steven M Paul; Laura B Dunn; Jon D Levine; Fay Wright; Marilyn J Hammer; Judy Mastick; Alan Venook; Bradley E Aouizerat; Christine Miaskowski Journal: Support Care Cancer Date: 2015-09-11 Impact factor: 3.603
Authors: Tito R Mendoza; Fengmin Zhao; Charles S Cleeland; Lynne I Wagner; Linda J Patrick-Miller; Michael J Fisch Journal: Clin Breast Cancer Date: 2013-06-28 Impact factor: 3.225
Authors: Julie L Otte; Janet S Carpenter; Shalini Manchanda; Kevin L Rand; Todd C Skaar; Michael Weaver; Yelena Chernyak; Xin Zhong; Christele Igega; Carol Landis Journal: Cancer Med Date: 2014-11-30 Impact factor: 4.452